Other ResourcesECHELON-1 Clinical Trial Web Site
Frontline Hodgkin Lymphoma Trial
ECHELON-1, Study ID: C25003
For more information on this clinical trial
This trial is currently enrolling patients in the following locations:
District of Columbia
Republic of Korea
Updated March 3, 2015
A phase 3 randomized, two-arm trial of brentuximab vedotin plus AVD (doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) as front-line therapy in patients with advanced classical Hodgkin lymphoma.
What is a phase 3 study?
A phase III study normally involves more patients than a phase 2 trial and confirms the efficacy of the study drug and compares it to commonly used therapies. They also generate long-term safety data for the study drug.
Who can participate?
- You are18 years or older with a diagnosis of classical Hodgkin lymphoma.
- You have not received prior therapy for this disease.
- At a minimum, you are able to move around and are capable of self-care. You are up and about more than half of waking hours.
Why is the study being done?
This study is being done to test the effectiveness of brentuximab vedotin when given to patients who have had no prior therapy for classical Hodgkin lymphoma. It will compare the study drug's effectiveness in combination with AVD to ABVD.